Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with O
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q2 2024 | OPASPRAY K-1-2656 BEIGE | ORAL | TABLET, FILM COATED | 3.36 mg | 7mg | Deletion | |
| Q1 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET | 38.00 mg | MDE Replacement | ||
| Q2 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET | 62mg | MDE Replacement | ||
| Q1 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET, EXTENDED RELEASE | 33.00 mg | MDE Replacement | ||
| Q2 2024 | OPADRY II Y-30-18037 WHITE | ORAL | TABLET, EXTENDED RELEASE | 88mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024